A review of mathematical models of HIV/AIDS interventions and their implications for policy

Sexually Transmitted Infections

Volumn 87, Issue 7, 2011, Pages 629-634

  Johnson, Leigh F ^a   White, Peter J ^b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; COST EFFECTIVENESS ANALYSIS; EPIDEMIC; HEALTH CARE POLICY; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MATHEMATICAL MODEL; MEDLINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; FEMALE; HEALTH POLICY; HUMANS; MALE; MODELS, THEORETICAL;

EID: 82555189805     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.2010.045500     Document Type: Review

References (65)

1. UNAIDS. 2008 Report on the Global AIDS Epidemic. Geneva. 2008. http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/ 2008-Global-report. asp (accessed 8 Aug 2008).
2. Piot P, Bartos M, Larson H, et al. Coming to terms with complexity: a call to action for HIV prevention. Lancet 2008;372:845-59.
3. Bertozzi SM, Laga M, Bautista-Arredondo S, et al. Making HIV prevention programmes work. Lancet 2008;372:831-44.
4. Anderson RM, Garnett GP. Mathematical models of the transmission and control of sexually transmitted diseases. Sex Transm Dis 2000;27:636-43.
5. Lasry A, Richter A, Lutscher F. Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health 2009;9 (Suppl 1):S8.
6. Stover J. Influence of mathematical modeling of HIV and AIDS on policies and programs in the developing world. Sex Transm Dis 2000;27:572-8.
7. Baggaley RF, Ferguson NM, Garnett GP. The epidemiological impact of antiretroviral use predicted by mathematical models: a review. Emerg Themes Epidemiol 2005;2:9.
8. Blower S, Bodine E, Kahn J, et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005;19:1-14. (Pubitemid 40111013)
9. Rowley J. Methodologies for Modeling the Impact of a Preventive AIDS Vaccine in Developing Countries: Recent Studies. International AIDS Vaccine Initiative Public Policy Department, 2005. Policy Research Working Paper 6. http://www.iavi.org (accessed 11 Mar 2006).
10. Hankins C, Abu Raddad L, Auvert B, et al. Male circumcision for HIV prevention in high HIV prevalence settings: what can mathematical modelling contribute to informed decision making? PLoS Med 2009;6:e1000109.
11. Cassels S, Clark SJ, Morris M. Mathematical models for HIV transmission dynamics: tools for social and behavioral science research. J Acquir Immune Defic Syndr 2008;47:S34-9. (Pubitemid 351323599)
12. Garnett GP, Anderson RM. Sexually transmitted diseases and sexual behaviour: insights from mathematical models. J Infect Dis 1996;174:S150-60.
13. Myers A, Myers J. Rolling out male circumcision as a mass HIV/AIDS intervention seems neither justified nor practicable. S Afr Med J 2008;98:781-2.
14. Londish GJ, Murray JM. Significant reduction in HIV prevalence according to male circumcision intervention in sub-Saharan Africa. Int J Epidemiol 2008;37:1246-53.
15. White RG, Glynn JR, Orroth KK, et al. Male circumcision for HIV prevention in sub-Saharan Africa: who, what and when? AIDS 2008;22:1841-50.
16. Hallett TB, Singh K, Smith JA, et al. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. PLoS One 2008;3:e2212.
17. Nagelkerke NJ, Moses S, de Vlas SJ, et al. Modelling the public health impact of male circumcision for HIV prevention in high prevalence areas in Africa. BMC Infect Dis 2007;7:16.
18. Boily MC, Desai K, Mâsse B, et al. Incremental role of male circumcision on a generalised HIV epidemic through its protective effect against other sexually transmitted infections: from efficacy to effectiveness to population-level impact. Sex Transm Infect 2008;84 (Suppl 2):ii28-34.
19. Wilson DP, Coplan PM, Wainberg MA, et al. The paradoxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci U S A 2008;105:9835-40. (Pubitemid 352031386)
20. Foss AM, Watts CH, Vickerman P, et al. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh? Addiction 2007;102:114-25. (Pubitemid 46006477)
21. Johnson LF, Dorrington RE, Bradshaw D, et al. Sexual behaviour patterns in South Africa and their association with the spread of HIV: insights from a mathematical model. Demographic Res 2009;21:289-340.
22. Sani A, Kroese DP. Controlling the number of HIV infectives in a mobile population. Math Biosci 2008;213:103-12.
23. Hallett TB, Garnett GP, Mupamberiyi Z, et al. Measuring effectiveness in community randomized trials of HIV prevention. Int J Epidemiol 2008;37:77-87. (Pubitemid 351228617)
24. Bezemer D, de Wolf F, Boerlijst MC, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS 2008;22:1071-7. (Pubitemid 351769746)
25. Boily M, Bastos FI, Desai K, et al. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections. Sex Transm Dis 2004;31:100-13.
26. Law MG, Prestage G, Grulich A, et al. Modelling the effects of combination antiretroviral treatments on HIV incidence. AIDS 2001;15:1287-94. (Pubitemid 32592362)
27. Blower SM, Aschenbach AN, Gershengorn HB, et al. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001;7:1016-20. (Pubitemid 32937381)
28. Smith RJ, Bodine EN, Wilson DP, et al. Evaluating the potential impact of vaginal microbicides to reduce the risk of acquiring HIV in female sex workers. AIDS 2005;19:413-21. (Pubitemid 40446188)
29. Foss AM, Vickerman PT, Heise L, et al. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003;17:1227-37. (Pubitemid 36675364)
30. Karmon E, Potts M, Getz WM. Microbicides and HIV: help or hindrance? J Acquir Immune Defic Syndr 2003;34:71-5. (Pubitemid 37100115)
31. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. J Acquir Immune Defic Syndr 2002;29:132-41. (Pubitemid 34164883)
32. Nagelkerke N, De Vlas S. The Epidemiological Impact of an HIV Vaccine on the HIV/AIDS Epidemic on Southern India. Washington, DC: World Bank, 2003. Policy research working paper 2978. http://www-wds.worldbank.org/external/ default/WDSContentServer/WDSP/IB/2003/03/22/000094946-03031204140842/additional/ 121521322-20041117164048.pdf (accessed 13 Jun 2011).
33. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS One 2007;2:e875.
34. Nagelkerke NJ, Jha P, de Vlas SJ, et al. Modelling HIV/AIDS epidemics in Botswana and India: impact of interventions to prevent transmission. Bull World Health Organ 2002;80:89-96. (Pubitemid 34205095)
35. Garnett GP, Bartley L, Grassly NC, et al. Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings. Nat Med 2002;8:651-4. (Pubitemid 34784602)
36. Basu S, Andrews JR, Poolman EM, et al. Prevention of nosocomial transmission of extensively drug-resistant tuberculosis in rural South African district hospitals: an epidemiological modelling study. Lancet 2007;370:1500-7. (Pubitemid 47628865)
37. Dowdy DW, Chaisson RE, Maartens G, et al. Impact of enhanced tuberculosis diagnosis in South Africa: a mathematical model of expanded culture and drug susceptibility testing. Proc Natl Acad Sci U S A 2008;105:11293-8.
38. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med 2006;3:e124.
39. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009;48:806-15.
40. Brown T, Salomon JA, Alkema L, et al. Progress and challenges in modelling country-level HIV/AIDS epidemics: the UNAIDS Estimation and Projection Package 2007. Sex Transm Infect 2008;84 (Suppl 1):i5-10.
41. Stover J, Johnson P, Zaba B, et al. The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect 2008;84 (Suppl 1):i24-30.
42. Stover J, Walker N, Garnett GP, et al. Can we reverse the HIV/AIDS pandemic with an expanded response? Lancet 2002;360:73-7. (Pubitemid 34756499)
43. Lyerla R, Gouws E, Garcia-Calleja JM, et al. The 2005 Workbook: an improved tool for estimating HIV prevalence in countries with low level and concentrated epidemics. Sex Transm Infect 2006;82 (Suppl 3):iii41-4. (Pubitemid 43901610)
44. Gouws E, White PJ, Stover J, et al. Short term estimates of adult HIV incidence by mode of transmission: Kenya and Thailand as examples. Sex Transm Infect 2006;82(Suppl 3):iii51-5. (Pubitemid 43901612)
45. Johnson LF, Dorrington RE. Modelling the demographic impact of HIV/AIDS in South Africa and the likely impact of interventions. Demographic Research 2006;14:541-74. (Pubitemid 43994815)
46. Cohen DA, Wu SY, Farley TA. Comparing the cost-effectiveness of HIV prevention interventions. J Acquir Immune Defic Syndr 2004;37:1404-14. (Pubitemid 39435055)
47. Rehle TM, Saidel TJ, Hassig SE, et al. AVERT: a user-friendly model to estimate the impact of HIV/sexually transmitted disease prevention interventions on HIV transmission. AIDS 1998;12:S27-35. (Pubitemid 28470172)
48. Dodd PJ, White PJ, Garnett GP. Notions of synergy for combinations of interventions against infectious diseases in heterogeneously mixing populations. Math Biosci 2010;227:94-104.
49. White RG, Orroth KK, Korenromp EL, et al. Can population differences explain the contrasting results of the Mwanza, Rakai, and Masaka HIV/sexually transmitted disease intervention trials? A modeling study. J Acquir Immune Defic Syndr 2004;37:1500-13. (Pubitemid 39602341)
50. Korenromp EL, White RG, Orroth KK, et al. Determinants of the impact of sexually transmitted infection treatment on prevention of HIV infection: a synthesis of evidence from the Mwanza, Rakai, and Masaka intervention trials. J Infect Dis 2005;191:S168-78.
51. Hallett TB, Aberle-Grasse J, Bello G, et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm Infect 2006;82 (Suppl 1):i1-8.
52. Boily MC, Pickles M, Vickerman P, et al. Using mathematical modelling to investigate the plausibility of attributing observed antenatal clinic declines to a female sex worker intervention in Karnataka state, India. AIDS 2008;22 (Suppl 5):S149-64.
53. Hallett TB, Gregson S, Mugurungi O, et al. Assessing evidence for behaviour change affecting the course of HIV epidemics: a new mathematical modelling approach and application to data from Zimbabwe. Epidemics 2009;1:108-17.
54. Vickerman P, Kumaranayake L, Balakireva O, et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm Dis 2006;33:S89-102.
55. White PJ, Ward H, Garnett GP. Is HIV out of control in the UK? An example of analysing patterns of HIV spreading using incidence-to-prevalence ratios. AIDS 2006;20:1898-901. (Pubitemid 44358912)
56. Walker PT, Hallett TB, White PJ, et al. Interpreting declines in HIV prevalence: impact of spatial aggregation and migration on expected declines in prevalence. Sex Transm Infect 2008;84 (Suppl 2):ii42-8.
57. Hallett TB, White PJ, Garnett GP. Appropriate evaluation of HIV prevention interventions: from experiment to full-scale implementation. Sex Transm Infect 2007;83 (Suppl 1):i55-60. (Pubitemid 47242474)
58. Boily MC, Abu-Raddad L, Desai K, et al. Measuring the public-health impact of candidate HIV vaccines as part of the licensing process. Lancet Infect Dis 2008;8:200-7. (Pubitemid 351249243)
59. Davenport MP, Ribeiro RM, Chao DL, et al. Predicting the impact of a non-sterilizing vaccine against human immunodeficiency virus. J Virol 2004;78:11340-51. (Pubitemid 39299675)
60. van Ballegooijen M, Bogaards JA, Weverling GJ, et al. AIDS vaccines that allow HIV-1 to infect and escape immunologic control: a mathematic analysis of mass vaccination. J Acquir Immune Defic Syndr 2003;34:214-20. (Pubitemid 37248919)
61. Anderson RM, Garnett GP. Low-efficacy HIV vaccines: potential for community-based intervention programmes. Lancet 1996;348:1010-13. (Pubitemid 26340759)
62. Johnson LF, Bekker LG, Dorrington RE. HIV/AIDS vaccination in adolescents would be efficient and practical when vaccine supplies are limited. Vaccine 2007;25:7502-9. (Pubitemid 47516618)
63. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010;24:729-35.
64. Kretzschmar M, Turner KM, Barton PM, et al. Predicting the population impact of chlamydia screening programmes: comparative mathematical modelling study. Sex Transm Infect 2009;85:359-66.
65. Brown T, Peerapatanapokin W. The Asian Epidemic Model: a processmodel for exploring HIV policy and programme alternatives in Asia. Sex Transm Infect 2004;80:i19-24. (Pubitemid 39070780)